NCT03727009 is a clinical trial of Blood Sample Collection in Hematologic Malignancy, sponsored by Exact Sciences Corporation.

Who is sponsoring NCT03727009?

NCT03727009 is sponsored by Exact Sciences Corporation.

What drugs are being tested in NCT03727009?

Interventions in NCT03727009: Blood Sample Collection.

What condition does NCT03727009 study?

NCT03727009 studies Hematologic Malignancy.

Is NCT03727009 still recruiting?

NCT03727009 is currently terminated. Last updated 3 February 2021.

Last reviewed 2021-02-03 · How we verify

NCT03727009

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies

Terminated Last updated 3 February 2021

What this trial tests

trial testing Blood Sample Collection in Hematologic Malignancy in 409 participants. Terminated before completion.

Timeline

7 December 2018

Primary endpoint
24 March 2020

24 March 2020

Quick facts

Lead sponsor	Exact Sciences Corporation
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	409
Start date	7 December 2018
Primary completion	24 March 2020
Estimated completion	24 March 2020
Sites	35 locations across United States

Drugs / interventions tested

Blood Sample Collection — full drug profile →

Conditions studied

Hematologic Malignancy — all drugs for Hematologic Malignancy →

Sponsor

Exact Sciences Corporation

Who can join

18 and older, any sex, with Hematologic Malignancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Liquid Biopsy in Cancer: Focus on Lymphoproliferative Disorders.
Savino FD, Rigali F, Giustini V, D'Aliberti D, et al · · 2022 · cited 6× · PMID 36358796 · DOI 10.3390/cancers14215378

Verify or expand the search:

Other trials of Blood Sample Collection

Trials testing the same drug.

NCT07436637 — Guardant Shield Colorectal Cancer Screening · NA · not yet recruiting
NCT07054346 — Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 · Phase 1 · recruiting
NCT06695494 — Enabling Genomic Testing in Cancer of Unknown Primary · recruiting
NCT07405515 — Pathophysiology of Dysautonomia and Postural Tachycardia Syndrome (POTS) in Post-viral Syndromes and COVID-19 · NA · active not recruiting
NCT05487248 — A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients · NA · active not recruiting

Other recruiting trials for Hematologic Malignancy

Currently open trials in the same condition.

NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07511127 — Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT · Phase 3 · recruiting
NCT07413991 — Expressive Writing Program Among Young Adults With Blood Cancer · NA · active not recruiting
NCT06487247 — HEME Home Transfusion Program · NA · recruiting
NCT07035938 — T-cell Developmental Status in Patients With Malignant Hematological Tumors · recruiting

Other Exact Sciences Corporation trials

Trials by the same sponsor.

NCT05246839 — Informed Choice - Compass · terminated
NCT05210283 — CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer · active not recruiting
NCT04473625 — Stool Collection Sub-Study of Exact Sciences Protocol 2018-01 · completed
NCT04395391 — Home Usability Study of the SARS-CoV-2 (COVID-19) Test · completed
NCT04213326 — Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03727009 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Exact Sciences Corporation
Last refreshed: 3 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03727009.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing